Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
Crossref DOI link: https://doi.org/10.1186/s12913-017-2118-2
Published Online: 2017-03-08
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wirth, Daniel
Dass, Ramesh
Hettle, Robert
Funding for this research was provided by:
Janssen-Cilag
